This post by MDV brings to my mind two mind boggling CD12
This post by MDV brings to my mind two mind boggling CD12 scenarios.
First, MDV offers the possibility that mortality is leronlimab dose-respondent.
Second, it occurs to me that RO could prove dose dependent life saving capability of LL, but Cytodyn doesn't have the data either because it was not done on all CD12 patients or because what RO data was collected is not in Cytodyn's possesion and is thus not presentable to the FDA.
"What I can say is in the first 100 patients there was quite a difference in RO between the two cohorts, survival data of course is forthcoming. Occupancy can vary amongst treated patient, but if those with the highest occupancy survive it could lead to fast track."
The first mind-boggling concept that MDV offers is the following:
What if the only CD12 patients who died were patients who had some "low" level of RO.
Maybe every patient who survived has RO greater than 90% at day seven, for example.
That is a p-value of of at least as good as .001.
This situation seems potentially possible to me as the dose of leronlimab was just grabbed from HIV.
Somewhat hilariously, the only way to set the dose for covid was to use the Patterson CCR5 RO data that was just rejected by the FDA for HIV!?!?!?!?!?!?
There have never been any dose limiting LL toxicities observed in humans.
Maybe covid just needs a higher dose than HIV.
We already have a very strong hypothesis that the dose method for covid is wrong and should be intravenous instead of subcutaneous.
Covid is an emergency condition. HIV is chronic.
Maybe the covid dose was not high enough and that's why the covid LL patients died. CD12 RO tests could indicate that if some LL CD12 patients had been given a higher LL dose, then all of the covid LL patients would have survived.
Well, even if that possibility doesn't make your head spin, then the second possibility could still make your head explode.
What if Cytodyn does not have the RO data that demonstrates that LL covid survival is dose dependent?
What if the reason is because CD12 RO was not done because of the split with Patterson?
What if some data is done, but Cytodyn doesn't have it because of their spat with Patterson?
3
1
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Trump's New Team: A Hope for Shareholder Relief? Picture the scene—Next Bridge Hydrocarbons, caught in the depths of shareholder unrest over the unresolved MMTLP fiasco, is looking to the top for answers. With a fresh face, Stephen Miller, stepping in as the White House Chief of Staff, there's a new angle at play. They're knocking on the doors of the Trump...
Continue Reading
Facchin Joins Reactive Technologies: Power Play or Predictable Move? Let me tell you, the energy sector ain’t for the faint-hearted—especially when you’re talking grid stability. Reactive Technologies just tossed an ace on the table, appointing Claudio Facchin as the new Board Chairman. If you've been around the block, you might recognize Facchin's name from his...
Continue Reading
Big Gains and Bigger Moves Ahead Here's a bit of sunshine for your investment portfolio: Innovative Eyewear's third-quarter results are packing quite the punch, showing a strong 51% uptick in revenue year-over-year. If you've got a stake in NASDAQ:LUCY, pay close attention. This ain't just a flash in the pan; it's a consistent rise, marking their 13th consecutive quarter...
Continue Reading
The overlooked hero in wall longevity People might think building a retaining wall is just stacking stones or pouring concrete, but that's only part of the story. According to Justin Hundich, our go-to guy on landscape and drainage matters, there's way more at play than meets the eye. If you ignore drainage, you're steaming toward disaster, my friend—no two ways about...
Continue Reading
Introduction to the Future of Solar Living Just when you thought you'd seen it all, along comes Outer Spaces with their OS1—a solar pavilion and battery deck that looks at residential energy with fresh eyes. Debuting at the RE+ 2026 in Las Vegas, this isn't just another gizmo. This is about bringing solar power to your backyard without making your roof look like it...
Continue Reading
Shokz's Big Leap With OpenHear BM420 Alright, this recognition for Shokz comes out of the left field for anyone not keeping an eye on their trajectory lately. From headphones to hearing aids—Shokz takes a genuine shot at making life easier for folks struggling with hearing issues. The CES 2027 Innovation Award for their OpenHear BM420 shows the tech's real potential in...
Continue Reading
Illinois Cranks Up the Heat on Low-Dose THC Drinks Illinois, you've really done it this time. When it comes to low-dose THC beverages, the state is setting up shop for illicit sellers by going harsher than federal standards. On November 12, these drinks, which have a loyal following, will be off the shelves—thanks to a reclassification that lumps them in with more...
Continue Reading
Krispy Kreme's Sugar-Coated Trouble Ah, Krispy Kreme, where donuts and legal woes seem to go hand in hand these days. Dropping donuts might be a morning mishap, but dropping a stock by 37%? Now that’s a disaster, especially when folks like Schubert Jonckheer & Kolbe smell a rat in the kitchen. Fresh Out of the Baker's Oven: Lawsuit Updates On August 26, 2026, a...
Continue Reading
Pioneering Cloud Seeding: Rainmaker's Big Talk Mornings like this, I find myself wondering if we're still all buying snake oil—or if the future just landed in our laps. Rainmaker Technology Corporation just dropped what might be a game-changer or a grand illusion for those of us with a finger on the pulse of water tech. Their study in 'Atmosphere' paints a picture of...
Continue Reading
ALP Swings Big in the Big Apple Here's a move that's about as loud as blaring your TV at midnight — ALP, the nicotine pouch brand that’s been taking quiet corners of rural America by storm, is barging into New York City with a brazen pop-up and a parade of marketing antics. Think of it as taking the Wild West and plunking it down in the urban jungle. They're...
Continue Reading
Top 5 Most Recently Viewed Articles
Invivyd's Upcoming Financial Results Conference Call Invivyd, Inc. (Nasdaq: IVVD), a pioneering leader in the biopharmaceutical industry, has exciting developments lined up for their investors. On an upcoming Thursday morning, the company will host a conference call aimed at discussing their financial performance and business strategies. This communication will take place...
Continue Reading
The emergence of young Chinese artists reshaped the cultural scene by fusing traditional elements with contemporary expressions. This isn’t just a passing phase; it’s a full-blown movement where the youth aren’t merely adopting global trends but redefining them with their unique insights. Take Liu Qingyi, for example. The 19-year-old breakdancer dazzled audiences at...
Continue Reading
STRATA Skin Sciences to Attend D. Boral Capital Conference STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a prominent medical technology company, is set to participate in the D. Boral Capital Inaugural Global Conference. This significant event will be held in a leading location, offering the perfect platform for STRATA to showcase its...
Continue Reading
Medecision Partners with Sendero Health Plans for Health Improvement Medecision, a leader in clinical data solutions, has announced an exciting partnership with Sendero Health Plans, a nonprofit healthcare organization. Together, they aim to significantly enhance health outcomes within the communities of Central Texas. Commitment to Quality Care Sendero Health Plans is...
Continue Reading
Julia Vorholt's Groundbreaking Research Professor Julia Vorholt has made significant contributions to our understanding of plant health through her pioneering research on plant microbiomes. Her work reveals that just like humans rely on beneficial gut bacteria, plants too harbor communities of microorganisms that play a vital role in their development. This revelation...
Continue Reading